Benazepril affects integrin-linked kinase and smooth muscle α-actin expression in diabetic rat glomerulus and cultured mesangial cells

BMC Nephrology

Ying Li¹  Tao Zhang¹  Yanqing Chi¹  Maodong Liu¹  Lei Nie²  Honglin Niu¹ 

[1] Key Laboratory of Kidney Diseases of Hebei Province, Shijiazhuang 050071, China;VA Connecticut Healthcare System, West Haven, Connecticut 06519, USA

关键词: Glomerular mesangial cells;    Benazepril;    Smooth muscle α-actin;    Integrin-linked kinase;    Diabetic nephropathy;   

Others  :  1082638
DOI  :  10.1186/1471-2369-15-135

 received in 2014-03-24, accepted in 2014-08-13,  发布年份 2014

【 摘 要 】

Background

Diabetic nephropathy (DN) is the leading cause of chronic kidney disease and is associated with excessive cardiovascular morbidity and mortality. The angiotensin converting enzyme inhibitor (ACEI) benazepril has been shown to slow the progression of chronic renal disease and have beneficial effects in patients with a combination of chronic renal disease and cardiovascular disease. Transforming growth factor-β₁ (TGF-β₁) plays a central role in the pathogenesis and progression of DN. Integrin-linked kinase (ILK) can modulate TGF-β₁-induced glomerular mesangial cell (GMC) injury, which is a prominent characteristic of renal pathology in kidney diseases. As an integrin cytoplasmic-binding protein, ILK regulates fibronectin (FN) matrix deposition and the actin cytoskeleton. Smooth muscle α-actin (α-SMA) is involved in progressive renal dysfunction in both human and experimental renal disease.

Methods

To explore the mechanisms of benazepril’s reno-protective effects, we examined the expression of TGF-β₁, ILK, and α-SMA in GMC exposed to high glucose (HG) and in the kidneys of streptozotocin (STZ)-induced diabetic rats using real-time quantitative RT-PCR and western blot analysis. To elucidate the mechanism(s) of the effect of benazepril on GMC cellular processes, we assessed the effect of benazepril on Angiotensin II (Ang II) signalling pathways using western blot analysis.

Results

The expression of TGF-β₁, ILK, and α-SMA increased significantly in the diabetic group compared with the control group. Benazepril treatment inhibited the expression of these genes in DN but failed to rescue the same levels in the control group. Similar results were found in GMC treated with HG or benazepril. Ang II increased ERK and Akt phosphorylation in the HG group, and benazepril could not completely block these responses, suggesting that other molecules might be involved in the progression of DN. Our findings suggest that benazepril decreases ILK and α-SMA expression, at least in part, by affecting the interactions between Ang II and TGF-β₁.

Conclusions

The findings described here support the hypothesis that the HG milieu of diabetes increases TGF-β₁ secretion, which increases the synthesis of ILK and α-SMA that are involved in the progression of DN. This might be an important mechanism of the benazepril renal-protective function in the pathogenesis of DN.

【 授权许可】

   
2014 Niu et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

Figure 6.

【 参考文献 】

• [1]Remuzzi G, Schieppati A, Ruggenenti P: Clinical practice. Nephropathy in patients with type 2 diabetes. N Engl J Med 2002, 346(15):1145-1151.
• [2]Sego S: Pathophysiology of diabetic nephropathy. Nephrol Nurs J 2007, 34(6):631-633.
• [3]Kanwar YS, Wada J, Sun L, Xie P, Wallner EI, Chen S, Chugh S, Danesh FR: Diabetic nephropathy: mechanisms of renal disease progression. Exp Biol Med (Maywood) 2008, 233(1):4-11.
• [4]Kim SM, Kim N, Lee S, Kim do K, Lee YM, Ahn SH, Song JH, Choi BK, Wu C, Jung KY: TGF-beta1-induced PINCH-1-ILK-alpha-parvin complex formation regulates mesangial cell proliferation and hypertrophy. Exp Mol Med 2007, 39(4):514-523.
• [5]Guo L, Sanders PW, Woods A, Wu C: The distribution and regulation of integrin-linked kinase in normal and diabetic kidneys. Am J Pathol 2001, 159(5):1735-1742.
• [6]Carey AV, Carey RM, Gomez RA: Expression of alpha-smooth muscle actin in the developing kidney vasculature. Hypertension 1992, 19(2 Suppl):II168-175.
• [7]Hu P, Qin YH, Pei J, Lei FY, Hu B, Lu L: Beneficial effect of all-trans retinoic acid (ATRA) on glomerulosclerosis rats via the down-regulation of the expression of alpha-smooth muscle actin: a comparative study between ATRA and benazepril. Exp Mol Pathol 2010, 89(1):51-57.
• [8]Jacobson HR: Chronic renal failure: pathophysiology. Lancet 1991, 338(8764):419-423.
• [9]Leehey DJ, Singh AK, Alavi N, Singh R: Role of angiotensin II in diabetic nephropathy. Kidney Int Suppl 2000, 77:S93-98.
• [10]Border WA, Noble NA: Evidence that TGF-beta should be a therapeutic target in diabetic nephropathy. Kidney Int 1998, 54(4):1390-1391.
• [11]Parving HH: Diabetic nephropathy: prevention and treatment. Kidney Int 2001, 60(5):2041-2055.
• [12]Jacobsen P, Rossing K, Parving HH: Single versus dual blockade of the renin-angiotensin system (angiotensin-converting enzyme inhibitors and/or angiotensin II receptor blockers) in diabetic nephropathy. Curr Opin Nephrol Hypertens 2004, 13(3):319-324.
• [13]Maschio G, Alberti D, Janin G, Locatelli F, Mann JF, Motolese M, Ponticelli C, Ritz E, Zucchelli P: Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group. N Engl J Med 1996, 334(15):939-945.
• [14]Satoh M, Fujimoto S, Haruna Y, Arakawa S, Horike H, Komai N, Sasaki T, Tsujioka K, Makino H, Kashihara N: NAD(P)H oxidase and uncoupled nitric oxide synthase are major sources of glomerular superoxide in rats with experimental diabetic nephropathy. Am J Physiol Renal Physiol 2005, 288(6):F1144-1152.
• [15]Parasuraman S, Raveendran R: Measurement of invasive blood pressure in rats. J Pharmacol Pharmacother 2012, 3(2):172-177.
• [16]Watson AM, Gray SP, Jiaze L, Soro-Paavonen A, Wong B, Cooper ME, Bierhaus A, Pickering R, Tikellis C, Tsorotes D, Thomas MC, Jandeleit-Dahm KA: Alagebrium reduces glomerular fibrogenesis and inflammation beyond preventing RAGE activation in diabetic apolipoprotein E knockout mice. Diabetes 2012, 61(8):2105-2113.
• [17]Okuda S, Languino LR, Ruoslahti E, Border WA: Elevated expression of transforming growth factor-beta and proteoglycan production in experimental glomerulonephritis. Possible role in expansion of the mesangial extracellular matrix. J Clin Invest 1990, 86(2):453-462.
• [18]Huang H, Li Y, Liu M, Shi Y, Zhang T: Gremlin induces cell proliferation and extra cellular matrix accumulation in mouse mesangial cells exposed to high glucose via the ERK1/2 pathway. BMC Nephrol 2013, 14(33):1471-2369.
• [19]Border WA, Ruoslahti E: Transforming growth factor-beta in disease: the dark side of tissue repair. J Clin Invest 1992, 90(1):1-7.
• [20]Sheetz MJ, King GL: Molecular understanding of hyperglycemia’s adverse effects for diabetic complications. Jama 2002, 288(20):2579-2588.
• [21]Vidotti DB, Casarini DE, Cristovam PC, Leite CA, Schor N, Boim MA: High glucose concentration stimulates intracellular renin activity and angiotensin II generation in rat mesangial cells. Am J Physiol Renal Physiol 2004, 286(6):F1039-1045.
• [22]Mondorf UF, Geiger H, Herrero M, Zeuzem S, Piiper A: Involvement of the platelet-derived growth factor receptor in angiotensin II-induced activation of extracellular regulated kinases 1 and 2 in human mesangial cells. FEBS Lett 2000, 472(1):129-132.
• [23]Wesson LG: Physical factors and glomerulosclerosis. Cause or coincidence? Nephron 1998, 78(2):125-130.
• [24]Lopez-Novoa JM, Rodriguez-Pena AB, Ortiz A, Martinez-Salgado C, Lopez Hernandez FJ: Etiopathology of chronic tubular, glomerular and renovascular nephropathies: clinical implications. J Transl Med 2011, 9:13. BioMed Central Full Text
• [25]Kolm V, Sauer U, Olgemoller B, Schleicher ED: High glucose-induced TGF-beta 1 regulates mesangial production of heparan sulfate proteoglycan. Am J Physiol 1996, 270(5 Pt 2):F812-821.
• [26]Oh JH, Ha H, Yu MR, Lee HB: Sequential effects of high glucose on mesangial cell transforming growth factor-beta 1 and fibronectin synthesis. Kidney Int 1998, 54(6):1872-1878.
• [27]Blattner SM, Kretzler M: Integrin-linked kinase in renal disease: connecting cell-matrix interaction to the cytoskeleton. Curr Opin Nephrol Hypertens 2005, 14(4):404-410.
• [28]Sanai T, Sobka T, Johnson T, el-Essawy M, Muchaneta-Kubara EC, Ben Gharbia O, el Oldroyd S, Nahas AM: Expression of cytoskeletal proteins during the course of experimental diabetic nephropathy. Diabetologia 2000, 43(1):91-100.
• [29]Xin C, Ren S, Eberhardt W, Pfeilschifter J, Huwiler A: The immunomodulator FTY720 and its phosphorylated derivative activate the Smad signalling cascade and upregulate connective tissue growth factor and collagen type IV expression in renal mesangial cells. Br J Pharmacol 2006, 147(2):164-174.
• [30]Burns KD: Angiotensin II and its receptors in the diabetic kidney. Am J Kidney Dis 2000, 36(3):449-467.
• [31]Awazu M, Ishikura K, Hida M, Hoshiya M: Mechanisms of mitogen-activated protein kinase activation in experimental diabetes. J Am Soc Nephrol 1999, 10(4):738-745.
• [32]Haneda M, Araki S, Togawa M, Sugimoto T, Isono M, Kikkawa R: Mitogen-activated protein kinase cascade is activated in glomeruli of diabetic rats and glomerular mesangial cells cultured under high glucose conditions. Diabetes 1997, 46(5):847-853.
• [33]Delcommenne M, Tan C, Gray V, Rue L, Woodgett J, Dedhar S: Phosphoinositide-3-OH kinase-dependent regulation of glycogen synthase kinase 3 and protein kinase B/AKT by the integrin-linked kinase. Proc Natl Acad Sci U S A 1998, 95(19):11211-11216.
• [34]Remy I, Montmarquette A, Michnick SW: PKB/Akt modulates TGF-beta signalling through a direct interaction with Smad3. Nat Cell Biol 2004, 6(4):358-365.
• [35]Hou FF, Zhang X, Zhang GH, Xie D, Chen PY, Zhang WR, Jiang JP, Liang M, Wang GB, Liu ZR, Geng RW: Efficacy and safety of benazepril for advanced chronic renal insufficiency. N Engl J Med 2006, 354(2):131-140.